We have previously demonstrated that for optimal tumor control, co-stimulatory antibodies such as OX40 antibody require different timing when compared to blocking antibodies such as anti-CTLA4 relative to the delivery of radiation therapy36. The gene discussed is CTLA4; the disease is neoplasm.